Kiniksa Pharmaceuticals, Ltd. (KNSA) key performance indicators and operating metrics (11 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| ARCALYST Prescribers | 5K | FY2026-Q2 |
| ARCALYST Collaboration Operating Profit | 176.1M | FY2026-Q2 |
| Multiple-Recurrence Target Population on ARCALYST Treatment | 21.00 percent | FY2026-Q2 |
| ARCALYST Net Product Revenue | 243.6M | FY2026-Q2 |
| Non-Cash Share-Based Compensation Expense | 11.6M | FY2026-Q2 |
| ARCALYST Collaboration Expenses | 88.1M | FY2026-Q2 |
| GB · Pharmaceutical revenue | 484K | FY2026-Q2 |
| Pharmaceutical · US revenue | 243.12M | FY2026-Q2 |
| ARCALYST Net Product Revenue Year-over-Year Growth | 56.00 percent | FY2026-Q1 |
| Multiple-Recurrence Target Patient Population | 14K | FY2026-Q2 |
| Average Total ARCALYST Therapy Duration | 3.00 | FY2025-Q4 |
Back to KNSA overview · KNSA earnings · KNSA holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.